We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Provectus Biopharmaceuticals Inc (PVCT) USD0.001

Sell:$0.0537 Buy:$0.0537 Change: $0.0005 (0.94%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $0.0005 (0.94%)
Deal now Deal for just £11.95 per trade in a Fund and Share Account
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $0.0005 (0.94%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing immunotherapy medicines for different diseases. Its immunotherapy medicines are based on a family of small molecules called halogenated xanthenes (HXs). Its lead HX molecule is named rose bengal disodium (RBD). Its product pipeline includes PV-10 and PH-10. PV-10 is an investigational cancer immunotherapy administered by intralesional (IL) injection and an injectable formulation of cGMP RBD, is undergoing clinical study for adult solid tumor cancers, such as melanoma and gastrointestinal (GI) tumors. PH-10 is an investigational immuno-dermatology agent administered as a topical gel and formulation of cGMP RBD, is undergoing monotherapy clinical study and preclinical study of combination therapy with approved drugs for inflammatory dermatoses. It is also developing clinical programs for the treatment of SARS-CoV-2, Gram-positive bacteria, Infectious Keratosis and others.

Contact details

10025 Investment Dr Ste 250
United States
+1 (865) 7694011

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$22.52 million
Shares in issue:
419.45 million
Off Exchange
United States
US dollar

Key personnel

  • Edward Pershing
    Chairman of the Board
  • Timothy Scott
  • Dominic Rodrigues
    Vice Chairman of the Board
  • Heather Raines
    Chief Financial Officer
  • Bruce Horowitz
    Chief Operating Officer, Director
  • Eric Wachter
    Chief Technology Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.